Sanjeev Khindri has sold LQDA and made no open-market buys since Jun 2026

Sanjeev Khindri, MB, ChB, is a biopharmaceutical executive and physician who serves as Chief Development Officer (CDO) of Liquidia Corporation, a clinical-stage biopharmaceutical company focused on pulmonary hypertension therapies.( He joined Liquidia in 2025 and, as CDO, leads and oversees the company’s development strategy and execution across its pipeline, including late-stage and life‑cycle programs in pulmonary arterial hypertension (PAH) and related indications.( As a corporate insider at Liquidia, Khindri has reported beneficial ownership in the company’s equity, including restricted stock units disclosed in a Form 3 filing with the U.S. Securities and Exchange Commission.(

Before joining Liquidia, Khindri held senior clinical development leadership roles in the biopharmaceutical industry, including serving as Senior Vice President, Clinical Development at Aerovate Therapeutics, a company developing therapies for cardiopulmonary diseases.( Trained as a physician, he holds the degree MB, ChB (Bachelor of Medicine, Bachelor of Surgery), reflecting a formal medical education that underpins his career in clinical research and drug development.(

Written by Perplexity from public sources.